CLAIMS

1. An L-tartrate salt of 5-chloro-thiophene-2-carboxylic acid [(S)-2-[2-methyl-3-(2-oxo-pyrrolidin-1-yl)-benzenesulfonylamino]-3-(4-methyl-piperazin-1-yl)-3-oxo-propyl]amide, which is crystalline.

2. The L-tartrate salt of 5-chloro-thiophene-2-carboxylic acid [(S)-2-[2-methyl-3-(2-oxo-pyrrolidin-1-yl)-benzenesulfonylamino]-3-(4-methyl-piperazin-1-yl)-3-oxo-propyl]amide according to claim 1, which has a powder X-ray diffraction pattern comprising peaks at angles 2 theta of about 9.2°, 9.6°, 12.4°, 15.6°, 16.1°, 16.4°, 17.9°, 18.9°, 19.5°, 20.5°, 21.3°, 24.0°, 24.5°, 24.6°, 25.3°, and 25.4°.

3. A process for the preparation of an L-tartrate salt of 5-chloro-thiophene-2-carboxylic acid [(S)-2-[2-methyl-3-(2-oxo-pyrrolidin-1-yl)-benzenesulfonylamino]-3-(4-methyl-piperazin-1-yl)-3-oxo-propyl]amide, which is crystalline, comprising reacting a free base form of 5-chloro-thiophene-2-carboxylic acid [(S)-2-[2-methyl-3-(2-oxo-pyrrolidin-1-yl)-benzenesulfonylamino]-3-(4-methyl-piperazin-1-yl)-3-oxo-propyl]amide with L-tartaric acid in a solvent.

4. The process according to claim 3, further comprising reacting 5-chloro-thiophene-2-carboxylic acid [2-amino-3-(4-methyl-piperazin-1-yl)-3-oxo-propyl]-amide with 2-methyl-3-(2-oxo-pyrrolidin-1-yl)-benzenesulfonyl chloride to produce the free base form of 5-chloro-thiophene-2-carboxylic acid [(S)-2-[2-methyl-3-(2-oxo-pyrrolidin-1-yl)-benzenesulfonylamino]-3-(4-methyl-piperazin-1-yl)-3-oxo-propyl]amide.

5. A pharmaceutical composition comprising an L-tartrate salt of 5-chloro-thiophene-2-carboxylic acid [(S)-2-[2-methyl-3-(2-oxo-pyrrolidin-1-yl)-benzenesulfonylamino]-3-(4-methyl-piperazin-1-yl)-3-oxo-propyl]amide, which is crystalline, and at least one pharmaceutically acceptable excipient.